Renata Szalai

Dr. Renata Szalai

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 February 2016 in Molecular Cytogenetics
Verified
Journal Article
Open access
PDF file
Hadzsiev KingaHadzsiev Kinga
Hadzsiev Kinga
KKKatalin Komlosi
Katalin Komlosi
MCMárta Czakó
Márta Czakó
BDBalazs Duga
Balazs Duga
RSRenata Szalai
Renata Szalai
BMBela Melegh
Bela Melegh
Kleefstra syndrome is a rare genetic disorder, with core phenotypic features encompassing developmental delay/intellectual disability, characteristic facial features – brachy(micro)cephaly, unusual shaped eyebrows, flat face with hypertelorism, short nose with anteverted nostrils, thickened lower lip, carpmouth with macroglossia - and childhood hypotonia. Some additional symptoms are observed in different percentage of the patients. Epilepsy is common symptom as well. The underlying cause of the syndrome is a submicroscopic deletion in the chromosomal region 9q34.3 or disruption of the euchromatin histone methyl transferase 1. We describe two Hungarian Kleefstra syndrome patients, one with the classic phenotype of the syndrome, the diagnosis was confirmed by subtelomeric FISH. Meanwhile in our second patient beside the classic phenotype a new symptom – abnormal antiepileptic drug metabolic response – could be observed. Subtelomere FISH confirmed the 9q34.3 terminal deletion. Because of the abnormal drug metabolism in our second patient, we performed array CGH analysis as well searching for other rearrangements. Array CGH analysis indicated a large – 1.211 Mb -, deletion only in the 9q subtelomeric region with breakpoints ch9:139,641,471-140,852,911. This is the first report on Kleefstra syndrome in patients describing a classical and a complex phenotype involving altered drug metabolism.

9 January 2015 in Pathology and Oncology Research
Verified
Journal Article
Closed access
PDF file
SKSümegi Katalin
Sümegi Katalin
Luca JaromiLuca Jaromi
Luca Jaromi
LMLili Magyari
Lili Magyari
EKErzsebet Kovesdi
Erzsebet Kovesdi
BDBalazs Duga
Balazs Duga
BMBela Melegh
Bela Melegh

3 September 2015 in BMC Genomic Data
Verified
Journal Article
Open access
PDF file
ANAgnes Nagy
Agnes Nagy
CSCsilla Sipeky
Csilla Sipeky
RSRenata Szalai
Renata Szalai
BMBela Imre Melegh
Bela Imre Melegh
PMPetra Matyas
Petra Matyas
KTKalman Toth
Kalman Toth
SLCO1B1 polymorphisms are relevant in statin pharmacokinetics. Aim of this study was to investigate the genetic variability and haplotype profile of SLCO1B1 polymorphisms in Roma and Hungarian populations. Genotypes of 470 Roma and 442 Hungarian subjects for c.388A > G, c.521T > C and c.1498-1331T > C polymorphisms were determined by PCR-RFLP assay. Using these SNPs eight different haplotypes could be differentiated. Differences were found between Roma and Hungarians in SLCO1B1 388AA (24.5 vs. 45.5 %), GG (33.4 vs. 17.9 %) genotypes, AG + GG (75.5 vs. 54.5 %) carriers, in G allele frequency (0.545 vs. 0.362), respectively (p < 0.001). The most common SLCO1B1 haplotype was the ht8 (GTT) both in Roma (43.6 %) and in Hungarian (59.1 %) samples. The ht6 (GCT) was not present in Roma population samples Haplotype analyses showed striking differences between the Roma and Hungarian samples in ht4 (ATT, 37.2 % vs 20.8 %), ht5 (GCC, 1.15 % vs. 3.62 %) and ht8 (GTT, 43.6 % vs. 59.1 %) haplotypes (p < 0.01), respectively. Linkage disequilibrium analysis showed that the studied variants are in different linkage disequilibrium patterns depending on the ethnic origin. Similarly to Caucasians the 388G is the minor allele in Hungarians, however, in Roma the 388A was found to be the minor allele contrary to Indians (India). The minor allele frequency of 521T > C and 1498-1331T > C SNPs are almost three times higher in Romas than in Indians (Singapore and Gujarati, respectively). Observed allele frequency for 1498-1331T > C polymorphism reflects the measured average European rates in Hungarians. The results can be applied in population specific treatment algorithms when developing effective programs for statin therapy.

1 June 2015 in Pharmacological Reports
Verified
Journal Article
Closed access
AWAgnes Weber
Agnes Weber
RSRenata Szalai
Renata Szalai
CSCsilla Sipeky
Csilla Sipeky
LMLili Magyari
Lili Magyari
MMMarton Melegh
Marton Melegh
BMBela Melegh
Bela Melegh

1 August 2020 in Experimental and Molecular Pathology
Verified
Journal Article
Closed access
RSRenata Szalai
Renata Szalai
BMBela I. Melegh
Bela I. Melegh
ATAgnes Till
Agnes Till
RRReka Ripszam
Reka Ripszam
GCGyorgyi Csabi
Gyorgyi Csabi
KHKinga Hadzsiev
Kinga Hadzsiev

1 November 2014 in Environmental Toxicology and Pharmacology
Verified
Journal Article
Closed access
RSRenata Szalai
Renata Szalai
LMLili Magyari
Lili Magyari
PMPetra Matyas
Petra Matyas
BDBalazs Duga
Balazs Duga
ZBZsolt Bánfai
Zsolt Bánfai
BMBela Melegh
Bela Melegh